Physician profile
Felecia E Smith
NPI 1427249457
$8,721.11
in general payments reported to CMS, 2019-2025
26 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,098 · 2024: $2,944 · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,584 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,583.51 |
| Education | $137.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,028.29 | 2023-2025 | Tavneos, Otezla, Evenity |
| Abbvie INC. | $1,519.44 | 2023-2025 | |
| Ucb, INC. | $1,145.78 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,080.49 | 2023-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $546.45 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $388.90 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $299.75 | 2023-2024 | Taltz |
| Novartis Pharmaceuticals Corporation | $251.38 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $208.03 | 2024-2025 | Lupkynis |
| Horizon Therapeutics Plc | $206.49 | 2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $166.81 | 2023-2025 | Idacio, Tyenne |
| Janssen Scientific Affairs, LLC | $142.24 | 2023-2024 | Tremfya |
| Octapharma USA, INC. | $125.00 | 2023-2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $123.55 | 2023-2025 | Strensiq |
| Organon LLC | $109.96 | 2023-2025 | Hadlima |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $83.65 | 2024-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.65 | 2024-2025 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $42.04 | 2025 | Orencia |
| Glaxosmithkline, LLC. | $37.57 | 2025 | Benlysta |
| Astellas Pharma US INC | $34.71 | 2024 | Veozah |
| Celltrion USA INC. | $26.68 | 2025 | Vegzelma |
| Tonix Medicines, INC. | $22.00 | 2025 | Tonmya |
| Neurometrix INC | $19.75 | 2023 | |
| Genentech USA, INC. | $18.59 | 2025 | Actemra |
| Sandoz INC. | $17.44 | 2025 | Jubbonti |
| Scilex Pharmaceuticals INC. | $16.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felecia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.